Genprex, Inc. Common Stock (GNPX)
Genprex, Inc. is a gene therapy company focused on developing immuno-oncology treatments for cancer. The company's lead product candidate is Oncoprex, an immunotherapy designed to activate the immune system to target tumors. Founded with the goal of advancing genetic medicine, Genprex develops innovative therapies aimed at improving outcomes for cancer patients.
Company News
Genprex's research collaborators will present positive preclinical data on the use of Reqorsa® Gene Therapy for treating Ras inhibitor resistant lung cancer, mesothelioma, and glioblastoma at the 2024 EORTC-NCI-AACR Symposium.
Genprex (GNPX) gains 9.5% after expanding clinical study sites in the United States for the early to mid-stage study of lead candidate, Reqorsa, to treat lung cancer patients.
NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- via InvestorWire — Genprex Inc. (NASDAQ: GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trusted brands within the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities.
Penny stocks under $1 to watch this week. The post Penny Stocks To Buy? 10 Under $1 To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.